MCID: PNC033
MIFTS: 64

Pancreas Adenocarcinoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Pancreas Adenocarcinoma

MalaCards integrated aliases for Pancreas Adenocarcinoma:

Name: Pancreas Adenocarcinoma 38 12
Pancreatic Adenocarcinoma 12 29 6 15
Adenocarcinoma of the Pancreas 12
Adenocarcinoma of Pancreas 73

Classifications:



External Ids:

Disease Ontology 12 DOID:4074
NCIt 50 C8294
SNOMED-CT 68 700423003
UMLS 73 C0281361

Summaries for Pancreas Adenocarcinoma

Disease Ontology : 12 A pancreatic carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Pancreas Adenocarcinoma, also known as pancreatic adenocarcinoma, is related to pancreatic cancer and adenocarcinoma, and has symptoms including abdominal pain, icterus and pruritus. An important gene associated with Pancreas Adenocarcinoma is SMAD4 (SMAD Family Member 4), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Abraxane and Gemzar have been mentioned in the context of this disorder. Affiliated tissues include pancreas, lung and endothelial, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 76 Pancreatic cancer arises when cells in the pancreas, a glandular organ behind the stomach, begin to... more...

Related Diseases for Pancreas Adenocarcinoma

Diseases related to Pancreas Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 150)
# Related Disease Score Top Affiliating Genes
1 pancreatic cancer 33.1 AKT1 CDKN2A CTNNB1 ERBB2 HRAS KRAS
2 adenocarcinoma 31.6 AKT1 CDKN2A CTNNB1 ERBB2 GNAS HRAS
3 cholangiocarcinoma 30.6 AKT1 CDKN2A CTNNB1 ERBB2 HRAS KRAS
4 apocrine adenoma 11.3 HRAS KRAS PIK3CA
5 mutyh-associated polyposis 11.3 KRAS SMAD4 TP53
6 adult hepatocellular carcinoma 11.3 CTNNB1 PIK3CA TP53
7 pancreatic ductal adenocarcinoma 11.3
8 anal canal adenocarcinoma 11.3 FOXP3 HRAS KRAS
9 aggressive digital papillary adenocarcinoma 11.3 HRAS KRAS PIK3CA
10 spitz nevus 11.3 CDKN2A HRAS TP53
11 colloid carcinoma of the pancreas 11.3 HRAS KRAS SMAD4
12 gallbladder adenoma 11.3 CDKN2A CTNNB1 HRAS
13 thyroid lymphoma 11.3 CDKN2A IL7 TP53
14 breast squamous cell carcinoma 11.3 ERBB2 PIK3CA TP53
15 adenosquamous pancreas carcinoma 11.3 HRAS KRAS SMAD4
16 lichen disease 11.3 FOXP3 IFNG TP53
17 primary peritoneal carcinoma 11.3 ERBB2 ERCC1 IFNG TP53
18 lung adenoid cystic carcinoma 11.3 HRAS KRAS PIK3CA
19 esophagus adenocarcinoma 11.3 ERBB2 PIK3CA SMAD4 TP53
20 biliary papillomatosis 11.3 HRAS KRAS TP53
21 nevus, epidermal 11.3 HRAS KRAS PIK3CA
22 prostate squamous cell carcinoma 11.3 HRAS PIK3CA TP53
23 ovary serous adenocarcinoma 11.3 GNAS HRAS KRAS
24 ovarian cystadenocarcinoma 11.3 GNAS HRAS KRAS
25 acinar cell carcinoma 11.3 CTNNB1 SMAD4 TP53
26 sigmoid neoplasm 11.3 HRAS KRAS
27 meningeal melanomatosis 11.3 CDKN2A HRAS TP53
28 oral leukoplakia 11.3 CDKN2A ERBB2 TP53
29 liver angiosarcoma 11.3 HRAS KRAS TP53
30 acneiform dermatitis 11.3 ERBB2 HRAS KRAS PIK3CA
31 mixed cell type cancer 11.3 ERBB2 HRAS KRAS TP53
32 ovary adenocarcinoma 11.3 ERBB2 HRAS KRAS TP53
33 ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3 11.3 CTNNB1 KRAS PIK3CA TP53
34 nasal cavity adenocarcinoma 11.3 CDKN2A HRAS KRAS TP53
35 pulmonic stenosis 11.3 HRAS KRAS MAP2K2
36 rare adenocarcinoma of the breast 11.3 AKT1 KRAS PIK3CA TP53
37 adenosquamous cell lung carcinoma 11.3 ERBB2 HRAS KRAS PIK3CA
38 intestinal benign neoplasm 11.2 CTNNB1 HRAS KRAS TP53
39 costello syndrome 11.2 HRAS KRAS MAP2K2
40 bile duct adenocarcinoma 11.2 HRAS KRAS TP53
41 oral cavity cancer 11.2 ERBB2 ERCC1 PIK3CA TP53
42 ovarian serous cystadenocarcinoma 11.2 ERBB2 HRAS PIK3CA TP53
43 colorectal adenoma 11.2 CTNNB1 HRAS KRAS TP53
44 colorectal adenocarcinoma 11.2 CTNNB1 HRAS KRAS TP53
45 renal cell carcinoma, papillary, 1 11.2 ERBB2 HRAS PIK3CA TP53
46 ovarian clear cell carcinoma 11.2 KRAS PIK3CA TP53
47 anal squamous cell carcinoma 11.2 AKT1 CDKN2A PIK3CA TP53
48 bladder squamous cell carcinoma 11.2 CDKN2A ERBB2 PIK3CA TP53
49 pancreatic ductal carcinoma 11.2 CDKN2A SMAD4 TP53
50 brain stem astrocytic neoplasm 11.2 CDKN2A TP53

Graphical network of the top 20 diseases related to Pancreas Adenocarcinoma:



Diseases related to Pancreas Adenocarcinoma

Symptoms & Phenotypes for Pancreas Adenocarcinoma

UMLS symptoms related to Pancreas Adenocarcinoma:


abdominal pain, icterus, pruritus

GenomeRNAi Phenotypes related to Pancreas Adenocarcinoma according to GeneCards Suite gene sharing:

26 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.07 PIK3CA HRAS KRAS
2 Decreased viability GR00106-A-0 10.07 KRAS
3 Decreased viability GR00221-A-1 10.07 AKT1 KRAS CDKN2A PIK3CA HRAS
4 Decreased viability GR00221-A-2 10.07 AKT1 KRAS PIK3CA HRAS
5 Decreased viability GR00221-A-3 10.07 AKT1 CDKN2A HRAS
6 Decreased viability GR00221-A-4 10.07 AKT1 CDKN2A PIK3CA
7 Decreased viability GR00301-A 10.07 KRAS
8 Decreased viability GR00381-A-1 10.07 KRAS
9 Decreased viability GR00402-S-2 10.07 CDKN2A PIK3CA HRAS KRAS AKT1
10 Decreased cell migration GR00055-A-1 9.63 MAP2K2 PIK3CA CTNNB1 HRAS KRAS AKT1
11 Decreased viability in esophageal squamous lineage GR00235-A 9.4 PALLD CDKN2A PIK3CA CTNNB1 ERBB2 SMAD4

MGI Mouse Phenotypes related to Pancreas Adenocarcinoma:

46 (show all 27)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.53 AKT1 CTNNB1 CDKN2A SLC29A1 PTF1A PIK3CA
2 cellular MP:0005384 10.49 AKT1 CTNNB1 CDKN2A MAP2K2 PALLD PTF1A
3 endocrine/exocrine gland MP:0005379 10.49 CTNNB1 CDKN2A AKT1 PTF1A PIK3CA ERCC1
4 growth/size/body region MP:0005378 10.49 AKT1 CTNNB1 CDKN2A SLC29A1 MAP2K2 PTF1A
5 cardiovascular system MP:0005385 10.47 AKT1 CTNNB1 CDKN2A PTF1A PIK3CA ERBB2
6 homeostasis/metabolism MP:0005376 10.46 CDKN2A AKT1 PIK3CA MAP2K2 PTF1A ERCC1
7 mortality/aging MP:0010768 10.4 CDKN2A AKT1 PIK3CA MAP2K2 PALLD PTF1A
8 immune system MP:0005387 10.39 CDKN2A AKT1 PIK3CA PTF1A CTNNB1 ERCC1
9 embryo MP:0005380 10.38 CDKN2A AKT1 CTNNB1 PALLD PTF1A PIK3CA
10 hematopoietic system MP:0005397 10.38 CDKN2A AKT1 PTF1A CTNNB1 ERCC1 SMAD4
11 integument MP:0010771 10.38 AKT1 CTNNB1 CDKN2A PIK3CA ERCC1 ERBB2
12 craniofacial MP:0005382 10.35 CTNNB1 PTF1A ERBB2 FOXP3 TP53 SMAD4
13 digestive/alimentary MP:0005381 10.35 CDKN2A CTNNB1 MAP2K2 PTF1A ERBB2 TP53
14 neoplasm MP:0002006 10.3 CTNNB1 CDKN2A AKT1 PTF1A PIK3CA ERBB2
15 nervous system MP:0003631 10.28 CDKN2A AKT1 PIK3CA PALLD PTF1A CTNNB1
16 liver/biliary system MP:0005370 10.25 AKT1 CTNNB1 CDKN2A PTF1A ERCC1 FOXP3
17 muscle MP:0005369 10.22 CDKN2A AKT1 CTNNB1 PIK3CA ERCC1 ERBB2
18 adipose tissue MP:0005375 10.18 AKT1 PIK3CA MAP2K2 ERCC1 TP53 SLC29A1
19 limbs/digits/tail MP:0005371 10.18 PTF1A CTNNB1 ERBB2 SMAD4 SLC29A1 TP53
20 no phenotypic analysis MP:0003012 10.18 CTNNB1 CDKN2A SLC29A1 PTF1A PIK3CA FOXP3
21 normal MP:0002873 10.15 AKT1 MAP2K2 PTF1A ERBB2 CTNNB1 TP53
22 hearing/vestibular/ear MP:0005377 10.05 MAP2K2 CTNNB1 TP53 GNAS FOXP3 KRAS
23 reproductive system MP:0005389 10 CDKN2A AKT1 PIK3CA CTNNB1 ERCC1 ERBB2
24 renal/urinary system MP:0005367 9.97 CTNNB1 ERCC1 SMAD4 TP53 GNAS FOXP3
25 respiratory system MP:0005388 9.9 AKT1 CTNNB1 CDKN2A PTF1A ERBB2 FOXP3
26 skeleton MP:0005390 9.83 AKT1 CTNNB1 CDKN2A SLC29A1 PTF1A PIK3CA
27 vision/eye MP:0005391 9.28 CDKN2A PTF1A PIK3CA MAP2K2 CTNNB1 TP53

Drugs & Therapeutics for Pancreas Adenocarcinoma

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Abraxane 18 49 PACLITAXEL Celgene October 2012
2
Gemzar 18 49 GEMCITABINE HYDROCHLORIDE Eli Lilly May 1996
3
Sutent 18 49 SUNITINIB MALATE Pfizer May 2011/ January 2006

Drugs for Pancreas Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 329)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Capecitabine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 154361-50-9 60953
2
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 95058-81-4 60750
3
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 33069-62-4 36314
4
Pancrelipase Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53608-75-6
5
Ethanol Approved Phase 4,Phase 2,Phase 1,Not Applicable 64-17-5 702
6
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 2078-54-8 4943
7
Desflurane Approved Phase 4 57041-67-5 42113
8
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
9 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
10 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
11 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
12 Albumin-Bound Paclitaxel Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
13 Antimitotic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
14 Antineoplastic Agents, Phytogenic Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
15 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
16 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
17 pancreatin Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
18 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
19 Anti-Infective Agents, Local Phase 4,Phase 2,Phase 1
20 Central Nervous System Depressants Phase 4,Phase 2,Not Applicable
21 Anesthetics Phase 4,Phase 2,Phase 1
22 Anesthetics, General Phase 4
23 Anesthetics, Inhalation Phase 4
24
Oxaliplatin Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 61825-94-3 5310940 9887054 43805 6857599
25
Fluorouracil Approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-21-8 3385
26
Darbepoetin alfa Approved, Investigational Phase 2, Phase 3 11096-26-7, 209810-58-2
27
Dexamethasone Approved, Investigational, Vet_approved Phase 2, Phase 3 50-02-2 5743
28
Docetaxel Approved, Investigational Phase 2, Phase 3,Phase 1 114977-28-5 148124
29
Irinotecan Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable,Early Phase 1 97682-44-5, 100286-90-6 60838
30
Levoleucovorin Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1 68538-85-2
31
Sorafenib Approved, Investigational Phase 3,Phase 2,Phase 1 284461-73-0 216239 406563
32
Cisplatin Approved Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1 15663-27-1 84093 441203 2767
33
Cetuximab Approved Phase 3,Phase 1,Phase 2,Not Applicable 205923-56-4 56842117 2333
34
Epirubicin Approved Phase 2, Phase 3,Phase 1 56420-45-2 41867
35
Ifosfamide Approved Phase 3,Phase 1,Phase 2 3778-73-2 3690
36
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 216974-75-3
37
Dalteparin Approved Phase 3,Phase 2 9005-49-6
38
Heparin Approved, Investigational Phase 3,Phase 2 9005-49-6 772 46507594
39
Benzocaine Approved, Investigational Phase 3,Phase 1,Phase 2 1994-09-7, 94-09-7 2337
40
Olaparib Approved Phase 3,Phase 2 763113-22-0 23725625
41
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
42
Clopidogrel Approved Phase 3 120202-66-6, 113665-84-2 60606
43
Ticlopidine Approved Phase 3 55142-85-3 5472
44
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 143 6006
45
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 59-30-3 6037
46 tannic acid Approved, Nutraceutical Phase 3,Phase 1,Phase 2
47
Camptothecin Experimental Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 7689-03-4
48
Rubitecan Investigational Phase 3 91421-42-0
49
Irofulven Investigational Phase 3,Phase 2 158440-71-2
50
tipifarnib Investigational Phase 3,Phase 2 192185-72-1 159324

Interventional clinical trials:

(show top 50) (show all 703)
# Name Status NCT ID Phase Drugs
1 Pharmacokinetic Study of Adjuvant Capecitabine After Resection of Pancreatic Adenocarcinoma Completed NCT00854477 Phase 4 capecitabine
2 Endoscopic Ultrasound-guided Celiac Plexus Neurolysis (EUS-CPN)With Alcohol in Unresectable Pancreatic Cancer: a Pilot Study Completed NCT00578279 Phase 4 dehydrated alcohol
3 CTC Pancreatic Adenocarcinoma Recruiting NCT02335151 Phase 4 Desflurane
4 Geriatric Assessment Directed Trial to Evaluate Gemcitabine +/- Nab-paclitaxel in Elderly Pancreatic Cancer Patients Recruiting NCT02812992 Phase 4 Nab-paclitaxel;Gemcitabine
5 The Effect of Gemcitabine Plus Nab-paclitaxel as Secondary Chemotherapy in Advanced Pancreatic Cancer Recruiting NCT03401827 Phase 4 Chemotherapy (Gemcitabine + nab-paclitaxel)
6 Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC Recruiting NCT03257033 Phase 4 Gemcitabine;nab-paclitaxel
7 A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic Cancer Active, not recruiting NCT02237157 Phase 4 Gemcitabine, local delivery
8 Pancreatic Enzyme Suppletion in Pancreatic Cancer Withdrawn NCT01401387 Phase 4
9 Gemcitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Unresectable Pancreatic Adenocarcinoma Unknown status NCT00075452 Phase 3 gemcitabine hydrochloride;oxaliplatin
10 A Study to See if hENT1 Testing on Tumour Tissue Can Predict Response to Treatment With Gemcitabine Chemotherapy and if a Different Chemotherapy Called FOLFOX is Better Than Gemcitabine in Metastatic Pancreas Cancer Unknown status NCT01586611 Phase 3 5FU, leucovorin, oxaliplatin;Gemcitabine
11 Neoadjuvant GTX With Chemoradiation for Pancreatic Cancer (Stage II/III) Unknown status NCT01065870 Phase 2, Phase 3 Neoadjuvant gemcitabine, capecitabine, and docetaxel;Gemcitabine, capecitabine, docetaxel followed by radiotherapy
12 PANVAC™-VF Vaccine for the Treatment of Metastatic Pancreatic Cancer After Failing a Gemcitabine-Containing Regimen Unknown status NCT00088660 Phase 3
13 Gemcitabine and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer Unknown status NCT00268411 Phase 3 gemcitabine hydrochloride;oxaliplatin
14 Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer Unknown status NCT00112658 Phase 2, Phase 3 fluorouracil;gemcitabine hydrochloride;irinotecan hydrochloride;leucovorin calcium;oxaliplatin
15 Nitrocamptothecin or Fluorouracil in Treating Patients With Recurrent or Refractory Pancreatic Cancer Unknown status NCT00005871 Phase 3 fluorouracil;rubitecan
16 Nitrocamptothecin Compared With Other Chemotherapy in Treating Patients With Recurrent or Refractory Cancer of the Pancreas Unknown status NCT00005870 Phase 3 fluorouracil;gemcitabine hydrochloride;mitomycin C;rubitecan
17 Gemcitabine With or Without Sorafenib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Unknown status NCT00541021 Phase 3 gemcitabine hydrochloride;sorafenib tosylate
18 Nitrocamptothecin Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer Unknown status NCT00005869 Phase 3 gemcitabine hydrochloride;rubitecan
19 Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma Completed NCT01746979 Phase 3 TH-302;Gemcitabine;Placebo (5 percent dextrose - D5W)
20 Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas Completed NCT00844649 Phase 3 Albumin-bound paclitaxel (ABI-007);Gemcitabine
21 Gemcitabine With or Without Capecitabine and/or Radiation Therapy or Gemcitabine With or Without Erlotinib in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery Completed NCT00634725 Phase 3 capecitabine;erlotinib hydrochloride;gemcitabine hydrochloride
22 Irofulven Compared With Fluorouracil in Treating Patients With Pancreatic Cancer Completed NCT00033735 Phase 3 fluorouracil;Irofulven
23 Gemcitabine or Combination Chemotherapy Followed by Chemoradiation for Stage IB, II, or III Pancreatic Cancer Completed NCT00960284 Phase 2, Phase 3 capecitabine;cisplatin;epirubicin hydrochloride;fluorouracil;gemcitabine hydrochloride
24 Study of the Efficacy and Safety of Glufosfamide Compared With Best Supportive Care in Metastatic Pancreatic Cancer Completed NCT00099294 Phase 3 Glufosfamide
25 Fluorouracil, Gemcitabine, and Radiation Therapy in Treating Patients With Cancer of the Pancreas Completed NCT00003216 Phase 3 fluorouracil;gemcitabine hydrochloride
26 Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer Completed NCT01360853 Phase 3 ON 01910.Na;Gemcitabine;Gemcitabine
27 S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer Completed NCT00075686 Phase 3 gemcitabine hydrochloride
28 Safety and Efficacy of G17DT Immunogen Combined With Gemcitabine vs. Gemcitabine in the Treatment of Advanced Pancreatic Carcinoma Completed NCT00044031 Phase 3
29 Gemcitabine With or Without Radiation Therapy in Treating Patients With Pancreatic Cancer Completed NCT00057876 Phase 3 Gemcitabine
30 Gemcitabine With or Without Combination Chemotherapy and Radiation Therapy in Treating Patients With Nonmetastatic Pancreatic Cancer That Cannot Be Removed By Surgery Completed NCT00416507 Phase 3 fluorouracil;gemcitabine hydrochloride;liposomal cisplatin
31 Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery Completed NCT00303758 Phase 3 cisplatin;fluorouracil;gemcitabine hydrochloride;leucovorin calcium
32 Gemcitabine With or Without Erlotinib in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer Completed NCT00026338 Phase 3 erlotinib hydrochloride;gemcitabine hydrochloride
33 Fluorouracil With or Without Cisplatin in Treating Patients With Advanced or Metastatic Cancer of the Pancreas Completed NCT00003029 Phase 3 cisplatin;fluorouracil
34 Gemcitabine With or Without Capecitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Completed NCT00032175 Phase 3 capecitabine;gemcitabine hydrochloride
35 Gemcitabine and Radiation Therapy Compared With Gemcitabine Alone in Treating Patients Who Have Undergone Surgery for Pancreatic Cancer Completed NCT00064207 Phase 2, Phase 3 gemcitabine hydrochloride
36 Gemcitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Completed NCT00058149 Phase 3 gemcitabine hydrochloride;oxaliplatin
37 Gemcitabine With or Without Capecitabine in Treating Patients With Advanced Pancreatic Cancer Completed NCT00030732 Phase 3 Gemcitabine + Capecitabine;Gemcitabine alone
38 Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Completed NCT00088894 Phase 3 gemcitabine hydrochloride
39 Surgery Followed by Radiation Therapy and Chemotherapy in Treating Patients With Cancer of the Pancreas Completed NCT00003049 Phase 3 fluorouracil;leucovorin calcium
40 Gemcitabine and Capecitabine With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Completed NCT00425360 Phase 3 capecitabine;gemcitabine hydrochloride
41 Gemcitabine With or Without Tipifarnib (R115777) in Treating Patients With Advanced Pancreatic Cancer Completed NCT00005648 Phase 3 Gemcitabine with R115777;Gemcitabine with Placebo
42 Two Chemotherapy Regimens Compared With Observation in Treating Patients With Completely Resected Pancreatic Cancer Completed NCT00058201 Phase 3 fluorouracil;gemcitabine hydrochloride;leucovorin calcium
43 Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic Cancer Completed NCT00024427 Phase 3 fluorouracil;gemcitabine hydrochloride;triacetyluridine
44 Detection of Circulating Tumor Cells for the Diagnostic of Pancreatic Adenocarcinoma. Recruiting NCT02072616 Phase 3
45 Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3) Recruiting NCT03377491 Phase 3 Gemcitabine;nab paclitaxel
46 EndoTAG-1 Plus Gemcitabine Versus Gemcitabine Alone in Patients With Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment Recruiting NCT03126435 Phase 3 EndoTAG-1;Gemcitabine;Gemcitabine
47 Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer Recruiting NCT01954992 Phase 3 Glufosfamide;Fluorouracil
48 A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma Recruiting NCT02993731 Phase 3 Napabucasin;Nab-paclitaxel;Gemcitabine
49 Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy Recruiting NCT02184195 Phase 3 Olaparib;Olaparib;Placebo;Placebo
50 Intrabdominal Hyperthermic Chemotherapy and Pancreatic Cancer Recruiting NCT03251365 Phase 2, Phase 3 HIPEC-gemcitabine

Search NIH Clinical Center for Pancreas Adenocarcinoma

Genetic Tests for Pancreas Adenocarcinoma

Genetic tests related to Pancreas Adenocarcinoma:

# Genetic test Affiliating Genes
1 Pancreatic Adenocarcinoma 29

Anatomical Context for Pancreas Adenocarcinoma

MalaCards organs/tissues related to Pancreas Adenocarcinoma:

41
Pancreas, Lung, Endothelial, Liver, T Cells, Lymph Node, Colon

Publications for Pancreas Adenocarcinoma

Articles related to Pancreas Adenocarcinoma:

(show top 50) (show all 685)
# Title Authors Year
1
Obstructive jaundice as primary presentation of a stage IIE Non-Hodgkin lymphoma: A decision making process between advanced lymphoma and locally advanced/metastatic pancreatic adenocarcinoma. ( 29547849 )
2018
2
Feasibility of EUS-guided Nd:YAG laser ablation of unresectable pancreatic adenocarcinoma. ( 29452076 )
2018
3
A Rare Multifocal Pattern of Type 2 Autoimmune Pancreatitis with Negative IgG4: A Potential Diagnostic Pitfall That May Mimic Multifocal Pancreatic Adenocarcinoma. ( 29681791 )
2018
4
Inhibition of CX<sub>3</sub>CR1 reduces cell motility and viability in pancreatic adenocarcinoma epithelial cells. ( 29274778 )
2018
5
Paraneoplastic Stiff Person Syndrome Secondary to Pancreatic Adenocarcinoma. ( 29110193 )
2018
6
KDM4D Predicts Recurrence in Exocrine Pancreatic Cells of Resection Margins from Patients with Pancreatic Adenocarcinoma. ( 29599352 )
2018
7
Perioperative outcomes and survival following neoadjuvant stereotactic body radiation therapy (SBRT) versus intensity-modulated radiation therapy (IMRT) in pancreatic adenocarcinoma. ( 29448308 )
2018
8
Qualitative and quantitative evaluation for morphological changes of the splenic artery in autoimmune pancreatitis: novel imaging findings for differentiation from pancreatic adenocarcinoma. ( 29948059 )
2018
9
The clinical utility of immunoglobulin G4 in the evaluation of autoimmune pancreatitis and pancreatic adenocarcinoma. ( 29033025 )
2018
10
Preface: pancreas adenocarcinoma. ( 28705000 )
2017
11
Irreversible electroporation as treatment of locally advanced and as margin accentuation in borderline resectable pancreatic adenocarcinoma. ( 28078482 )
2017
12
Reduced morbidity with minimally invasive distal pancreatectomy for pancreatic adenocarcinoma. ( 28161217 )
2017
13
Identification of a Drug Targeting an Intrinsically Disordered Protein Involved in Pancreatic Adenocarcinoma. ( 28054562 )
2017
14
Pancreatic adenocarcinoma up-regulated factor has oncogenic functions in oral squamous cell carcinoma. ( 27706833 )
2017
15
Circulating interleukin-18 (IL-18) is a predictor of response to gemcitabine based chemotherapy in patients with pancreatic adenocarcinoma. ( 28087305 )
2017
16
PAP/REG3A favors perineural invasion in pancreatic adenocarcinoma and serves as a prognostic marker. ( 28656348 )
2017
17
Pancreas adenocarcinoma: novel therapeutics. ( 28705007 )
2017
18
Evaluation of Plasma MicroRNAs as Diagnostic and Prognostic Biomarkers in Pancreatic Adenocarcinoma: miR-196a and miR-210 Could Be Negative and Positive Prognostic Markers, Respectively. ( 28466015 )
2017
19
Downregulation of ULK1 by microRNA-372 inhibits the survival of human pancreatic adenocarcinoma cells. ( 28677209 )
2017
20
Strategies to improve local control of resected pancreas adenocarcinoma. ( 28317586 )
2017
21
Overexpression of Topoisomerase 2-Alpha Confers a Poor Prognosis in Pancreatic Adenocarcinoma Identified by Co-Expression Analysis. ( 28815403 )
2017
22
Visceral Thromboses in Pancreas Adenocarcinoma: Systematic Review. ( 29306522 )
2017
23
Discrimination of CD44 and Oct3/4 Expression in Pancreatic Adenocarcinoma from Benign Pancreatic Ducts in Small Biopsy Specimens. ( 28464601 )
2017
24
Chimeric antigen receptor (CAR) T and other T cell strategies for pancreas adenocarcinoma. ( 29156888 )
2017
25
Differentially regulated ADAMTS1, 8, 9, and 18 in pancreas adenocarcinoma. ( 29358995 )
2017
26
Protocol of the PANCALYZE trial: a multicenter, prospective study investigating the tumor biomarkers CXCR4, SMAD4, SOX9 and IFIT3 in patients with resected pancreatic adenocarcinoma to predict the pattern of recurrence of the disease. ( 28356064 )
2017
27
Novel quantitative analysis of the S100P protein combined with endoscopic ultrasound-guided fine needle aspiration cytology in the diagnosis of pancreatic adenocarcinoma. ( 28260012 )
2017
28
Suppression of pancreatic adenocarcinoma upregulated factor (PAUF) increases the sensitivity of pancreatic cancer to gemcitabine and 5FU, and inhibits the formation of pancreatic cancer stem like cells. ( 29100320 )
2017
29
Upregulation of RET induces perineurial invasion of pancreatic adenocarcinoma. ( 28092668 )
2017
30
Evaluation of K-ras and p53 expression in pancreatic adenocarcinoma using the cancer genome atlas. ( 28742845 )
2017
31
Advanced pancreatic adenocarcinoma outcomes with transition from devolved to centralised care in a regional Cancer Centre. ( 28081546 )
2017
32
Progesterone inhibits proliferation and modulates expression of proliferation-Related genes in classical progesterone receptor-negative human BxPC3 pancreatic adenocarcinoma cells. ( 27449817 )
2017
33
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab or Placebo in Combination with Gemcitabine for the First-Line Treatment of Pancreatic Adenocarcinoma. ( 28246206 )
2017
34
IntegrinI^1 modulates tumour resistance to gemcitabine and serves as an independent prognostic factor in pancreatic adenocarcinomas. ( 27289231 )
2016
35
Increased B7H4 tissue expression correlates with high CA19.9 serum levels and a worse prognosis of pancreatic adenocarcinoma. ( 25924930 )
2016
36
Biomarkers in pancreatic adenocarcinoma: current perspectives. ( 28003762 )
2016
37
Percutaneous Image-Guided Irreversible Electroporation for the Treatment of Unresectable, Locally Advanced Pancreatic Adenocarcinoma. ( 27993507 )
2016
38
Bisdemethoxycurcumin exerts pro-apoptotic effects in human pancreatic adenocarcinoma cells through mitochondrial dysfunction and a GRP78-dependent pathway. ( 27845899 )
2016
39
A hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation therapy of borderline resectable and locally advanced pancreatic adenocarcinoma. ( 27532020 )
2016
40
Pancreatic Adenocarcinoma Complicated by Sinistral Portal Hypertension. ( 27555987 )
2016
41
T-cell programming in pancreatic adenocarcinoma: a review. ( 27910859 )
2016
42
CDX2 inhibits pancreatic adenocarcinoma cell proliferation via promoting tumor suppressor miR-615-5p. ( 26269116 )
2016
43
Targeted next generation sequencing of endoscopic ultrasound acquired cytology from ampullary and pancreatic adenocarcinoma has the potential to aid patient stratification for optimal therapy selection. ( 27203738 )
2016
44
Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy. ( 26439702 )
2016
45
Using next-generation sequencing to determine potential molecularly guided therapy options for patients with resectable pancreatic adenocarcinoma. ( 26754455 )
2016
46
Pancreatic adenocarcinoma up-regulated factor (PAUF) enhances the accumulation and functional activity of myeloid-derived suppressor cells (MDSCs) in pancreatic cancer. ( 27322081 )
2016
47
Synchronous pancreatic adenocarcinoma and intrahepatic cholangiocarcinoma arising in the context of intraductal papillary neoplasms. ( 27183137 )
2016
48
Dual oxidase 2 and pancreatic adenocarcinoma: IFN-I^-mediated dual oxidase 2 overexpression results in H2O2-induced, ERK-associated up-regulation of HIF-1I+ and VEGF-A. ( 27637085 )
2016
49
The role of contrast-enhanced endoscopic ultrasound in pancreatic adenocarcinoma. ( 28000627 )
2016
50
Peripheral ENO1-specific T cells mirror the intratumoral immune response and their presence is a potential prognostic factor for pancreatic adenocarcinoma. ( 27210467 )
2016

Variations for Pancreas Adenocarcinoma

ClinVar genetic disease variations for Pancreas Adenocarcinoma:

6
(show top 50) (show all 698)
# Gene Variation Type Significance SNP ID Assembly Location
1 PALLD NM_001166110.1(PALLD): c.415C> T (p.Pro139Ser) single nucleotide variant risk factor rs121908291 GRCh37 Chromosome 4, 169799457: 169799457
2 PALLD NM_001166110.1(PALLD): c.415C> T (p.Pro139Ser) single nucleotide variant risk factor rs121908291 GRCh38 Chromosome 4, 168878306: 168878306
3 MAP2K2 NM_030662.3(MAP2K2): c.169T> G (p.Phe57Val) single nucleotide variant Pathogenic rs121434498 GRCh37 Chromosome 19, 4117551: 4117551
4 MAP2K2 NM_030662.3(MAP2K2): c.169T> G (p.Phe57Val) single nucleotide variant Pathogenic rs121434498 GRCh38 Chromosome 19, 4117553: 4117553
5 SMAD4 NM_005359.5(SMAD4): c.1081C> T (p.Arg361Cys) single nucleotide variant Pathogenic rs80338963 GRCh37 Chromosome 18, 48591918: 48591918
6 SMAD4 NM_005359.5(SMAD4): c.1081C> T (p.Arg361Cys) single nucleotide variant Pathogenic rs80338963 GRCh38 Chromosome 18, 51065548: 51065548
7 SMAD4 NM_005359.5(SMAD4): c.1157G> A (p.Gly386Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121912580 GRCh37 Chromosome 18, 48593406: 48593406
8 SMAD4 NM_005359.5(SMAD4): c.1157G> A (p.Gly386Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121912580 GRCh38 Chromosome 18, 51067036: 51067036
9 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
10 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh38 Chromosome 17, 7674221: 7674221
11 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
12 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 GRCh38 Chromosome 17, 7674230: 7674230
13 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 GRCh37 Chromosome 17, 7577547: 7577547
14 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 GRCh38 Chromosome 17, 7674229: 7674229
15 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
16 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh38 Chromosome 17, 7674220: 7674220
17 TP53 NM_000546.5(TP53): c.814G> T (p.Val272Leu) single nucleotide variant Likely pathogenic rs121912657 GRCh37 Chromosome 17, 7577124: 7577124
18 TP53 NM_000546.5(TP53): c.814G> T (p.Val272Leu) single nucleotide variant Likely pathogenic rs121912657 GRCh38 Chromosome 17, 7673806: 7673806
19 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
20 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh38 Chromosome 17, 7674241: 7674241
21 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Pathogenic rs28934574 GRCh37 Chromosome 17, 7577094: 7577094
22 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Pathogenic rs28934574 GRCh38 Chromosome 17, 7673776: 7673776
23 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
24 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 GRCh38 Chromosome 17, 7674230: 7674230
25 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
26 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh38 Chromosome 17, 7673802: 7673802
27 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
28 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Likely pathogenic rs28934874 GRCh38 Chromosome 17, 7675161: 7675161
29 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
30 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh38 Chromosome 17, 7675161: 7675161
31 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
32 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 GRCh38 Chromosome 17, 7674872: 7674872
33 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
34 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
35 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
36 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh38 Chromosome 11, 534288: 534288
37 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
38 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh38 Chromosome 11, 534286: 534286
39 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
40 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
41 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
42 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh38 Chromosome 3, 179234297: 179234297
43 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
44 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 GRCh38 Chromosome 3, 179234297: 179234297
45 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh38 Chromosome 3, 179218304: 179218304
46 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
47 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh38 Chromosome 3, 179218303: 179218303
48 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 NCBI36 Chromosome 3, 180418785: 180418785
49 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
50 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092

Cosmic variations for Pancreas Adenocarcinoma:

9
(show top 50) (show all 3006)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM5575790 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.1159G>A p.A387T 18:25226759-25226759 8
2 COSM5576102 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.443G>A p.C148Y 18:25227475-25227475 8
3 COSM5576231 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.3434T>G p.V1145G 18:25224484-25224484 8
4 COSM5575704 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.2285G>A p.R762H 18:25225633-25225633 8
5 COSM5576098 ZNF384 stomach,NS,carcinoma,adenocarcinoma c.1136G>A p.R379Q 12:6669044-6669044 8
6 COSM3732832 ZNF341 stomach,NS,carcinoma,adenocarcinoma c.2512G>A p.A838T 20:33791485-33791485 8
7 COSM6964818 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.5929G>C p.G1977R 16:72796753-72796753 8
8 COSM6953000 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.4553G>T p.G1518V 16:72798129-72798129 8
9 COSM6965918 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.795C>A p.D265E 16:72959351-72959351 8
10 COSM6826469 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.1858C>T p.H620Y 16:72958288-72958288 8
11 COSM6941990 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.1081G>A p.G361R 16:72959065-72959065 8
12 COSM6986594 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.8198G>T p.R2733L 16:72794484-72794484 8
13 COSM6934198 YES1 stomach,NS,carcinoma,adenocarcinoma c.350G>A p.R117K 18:751726-751726 8
14 COSM6944960 YAP1 stomach,NS,carcinoma,adenocarcinoma c.356C>G p.T119S 11:102114178-102114178 8
15 COSM6951579 XRCC2 stomach,NS,carcinoma,adenocarcinoma c.140A>G p.H47R 7:152649345-152649345 8
16 COSM5576197 XPO1 stomach,NS,carcinoma,adenocarcinoma c.479G>A p.S160N 2:61499824-61499824 8
17 COSM185632 WT1 stomach,NS,carcinoma,adenocarcinoma c.869C>T p.T290M 11:32399973-32399973 8
18 COSM926359 WT1 stomach,NS,carcinoma,adenocarcinoma c.1298G>A p.R433H 11:32389110-32389110 8
19 COSM6906958 WT1 stomach,NS,carcinoma,adenocarcinoma c.122C>T p.A41V 11:32435020-32435020 8
20 COSM20570 WEE2 stomach,NS,carcinoma,adenocarcinoma c.996C>G p.N332K 7:141723249-141723249 8
21 COSM3732971 USH2A stomach,NS,carcinoma,adenocarcinoma c.8488A>T p.I2830F 1:215878834-215878834 8
22 COSM3732707 USH2A stomach,NS,carcinoma,adenocarcinoma c.140A>T p.K47M 1:216422197-216422197 8
23 COSM3732771 USH2A stomach,NS,carcinoma,adenocarcinoma c.11815G>A p.E3939K 1:215728281-215728281 8
24 COSM3732767 USH2A stomach,NS,carcinoma,adenocarcinoma c.11734G>A p.E3912K 1:215728362-215728362 8
25 COSM3732855 USH2A stomach,NS,carcinoma,adenocarcinoma c.11927C>T p.T3976M 1:215728169-215728169 8
26 COSM1094394 UBR5 stomach,NS,carcinoma,adenocarcinoma c.5561G>A p.R1854H 8:102285262-102285262 8
27 COSM5575712 UBR5 stomach,NS,carcinoma,adenocarcinoma c.5261G>A p.R1754Q 8:102285736-102285736 8
28 COSM6928622 U2AF1 stomach,NS,carcinoma,adenocarcinoma c.68A>G p.K23R 21:43104379-43104379 8
29 COSM3793896 TSHR stomach,NS,carcinoma,adenocarcinoma c.909G>C p.E303D 14:81142967-81142967 8
30 COSM6949448 TSHR stomach,NS,carcinoma,adenocarcinoma c.256G>A p.D86N 14:81068267-81068267 8
31 COSM6505728 TSC2 stomach,NS,carcinoma,adenocarcinoma c.5377C>T p.R1793W 16:2088563-2088563 8
32 COSM5576247 TSC2 stomach,NS,carcinoma,adenocarcinoma c.2803G>T p.A935S 16:2076551-2076551 8
33 COSM6922577 TSC2 stomach,NS,carcinoma,adenocarcinoma c.3820T>C p.S1274P 16:2082441-2082441 8
34 COSM5575753 TSC2 stomach,NS,carcinoma,adenocarcinoma c.2357G>A p.R786H 16:2074201-2074201 8
35 COSM6921200 TSC2 stomach,NS,carcinoma,adenocarcinoma c.445A>G p.N149D 16:2054404-2054404 8
36 COSM6915776 TSC1 stomach,NS,carcinoma,adenocarcinoma c.2066G>A p.R689H 9:132903793-132903793 8
37 COSM6963024 TSC1 stomach,NS,carcinoma,adenocarcinoma c.2161C>T p.R721C 9:132903698-132903698 8
38 COSM5576069 TSC1 stomach,NS,carcinoma,adenocarcinoma c.2143C>T p.R715W 9:132903716-132903716 8
39 COSM6924108 TSC1 stomach,NS,carcinoma,adenocarcinoma c.3185G>A p.R1062Q 9:132896545-132896545 8
40 COSM6952020 TSC1 stomach,NS,carcinoma,adenocarcinoma c.941C>T p.T314M 9:132911541-132911541 8
41 COSM6915052 TSC1 stomach,NS,carcinoma,adenocarcinoma c.1906G>A p.E636K 9:132905672-132905672 8
42 COSM5575742 TRRAP stomach,NS,carcinoma,adenocarcinoma c.622G>A p.E208K 7:98897855-98897855 8
43 COSM20551 TRRAP stomach,NS,carcinoma,adenocarcinoma c.5117G>A p.R1706H 7:98950120-98950120 8
44 COSM2866680 TRRAP stomach,NS,carcinoma,adenocarcinoma c.5956C>T p.R1986W 7:98956239-98956239 8
45 COSM5575878 TRRAP stomach,NS,carcinoma,adenocarcinoma c.10447G>A p.A3483T 7:99005171-99005171 8
46 COSM20550 TRRAP stomach,NS,carcinoma,adenocarcinoma c.477A>G p.K159K 7:98895790-98895790 8
47 COSM5576201 TRRAP stomach,NS,carcinoma,adenocarcinoma c.2075A>G p.Y692C 7:98912089-98912089 8
48 COSM5576203 TRRAP stomach,NS,carcinoma,adenocarcinoma c.8165C>T p.P2722L 7:98976763-98976763 8
49 COSM20561 TRPM7 stomach,NS,carcinoma,adenocarcinoma c.2488A>G p.M830V 15:50609673-50609673 8
50 COSM1542406 TRIO stomach,NS,carcinoma,adenocarcinoma c.6611A>G p.K2204R 5:14482727-14482727 8

Expression for Pancreas Adenocarcinoma

Search GEO for disease gene expression data for Pancreas Adenocarcinoma.

Pathways for Pancreas Adenocarcinoma

Pathways related to Pancreas Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 157)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.99 AKT1 CDKN2A CTNNB1 ERBB2 GNAS HRAS
2
Show member pathways
13.84 AKT1 CDKN2A ERBB2 GNAS HRAS KRAS
3
Show member pathways
13.84 AKT1 CTNNB1 ERBB2 HRAS KRAS MAP2K2
4
Show member pathways
13.81 AKT1 ERBB2 GNAS HRAS IFNG IL7
5
Show member pathways
13.67 AKT1 CTNNB1 ERBB2 GNAS HRAS KRAS
6
Show member pathways
13.65 AKT1 ERBB2 GNAS HRAS IFNG IL7
7
Show member pathways
13.64 AKT1 CTNNB1 ERBB2 HRAS KRAS MAP2K2
8
Show member pathways
13.51 AKT1 ERBB2 HRAS IFNG IL7 KRAS
9
Show member pathways
13.42 AKT1 CTNNB1 ERBB2 HRAS IL7 KRAS
10
Show member pathways
13.4 AKT1 CTNNB1 ERBB2 GNAS HRAS KRAS
11
Show member pathways
13.18 AKT1 GNAS HRAS KRAS MAP2K2 TP53
12
Show member pathways
13.18 AKT1 CDKN2A CTNNB1 GNAS HRAS KRAS
13
Show member pathways
13.17 AKT1 CDKN2A CTNNB1 GNAS HRAS KRAS
14
Show member pathways
13.16 AKT1 CTNNB1 GNAS HRAS KRAS MAP2K2
15
Show member pathways
13.15 AKT1 GNAS HRAS KRAS MAP2K2 PIK3CA
16
Show member pathways
13.11 AKT1 CTNNB1 ERBB2 GNAS HRAS IL7
17
Show member pathways
13.07 AKT1 GNAS HRAS KRAS MAP2K2 PIK3CA
18
Show member pathways
13.06 AKT1 CTNNB1 ERBB2 HRAS KRAS MAP2K2
19
Show member pathways
13.04 AKT1 ERBB2 HRAS KRAS MAP2K2 PIK3CA
20
Show member pathways
13.04 AKT1 HRAS IL7 KRAS MAP2K2 PIK3CA
21
Show member pathways
13.03 AKT1 ERBB2 GNAS HRAS KRAS MAP2K2
22
Show member pathways
12.99 AKT1 CTNNB1 HRAS KRAS TP53
23
Show member pathways
12.97 AKT1 CDKN2A HRAS KRAS MAP2K2 PIK3CA
24
Show member pathways
12.95 AKT1 CTNNB1 GNAS HRAS KRAS MAP2K2
25
Show member pathways
12.94 AKT1 GNAS HRAS IFNG KRAS MAP2K2
26
Show member pathways
12.94 AKT1 CDKN2A CTNNB1 ERBB2 HRAS KRAS
27
Show member pathways
12.92 AKT1 CDKN2A ERBB2 GNAS HRAS KRAS
28 12.91 AKT1 ERBB2 HRAS KRAS MAP2K2 TP53
29
Show member pathways
12.9 AKT1 IFNG MAP2K2 PIK3CA TP53
30
Show member pathways
12.9 AKT1 ERBB2 HRAS KRAS MAP2K2
31
Show member pathways
12.89 AKT1 CTNNB1 GNAS HRAS KRAS MAP2K2
32
Show member pathways
12.88 AKT1 ERBB2 HRAS KRAS PIK3CA TP53
33
Show member pathways
12.87 AKT1 CTNNB1 ERBB2 HRAS KRAS MAP2K2
34
Show member pathways
12.85 AKT1 GNAS HRAS KRAS MAP2K2
35
Show member pathways
12.82 AKT1 HRAS IFNG KRAS MAP2K2 TP53
36
Show member pathways
12.82 AKT1 CTNNB1 GNAS HRAS KRAS MAP2K2
37
Show member pathways
12.79 AKT1 GNAS HRAS KRAS MAP2K2
38
Show member pathways
12.78 AKT1 HRAS IFNG IL7 PIK3CA
39
Show member pathways
12.75 AKT1 CTNNB1 ERBB2 HRAS IFNG KRAS
40
Show member pathways
12.73 AKT1 CTNNB1 HRAS KRAS MAP2K2 PIK3CA
41
Show member pathways
12.73 AKT1 CDKN2A CTNNB1 ERBB2 HRAS KRAS
42
Show member pathways
12.72 AKT1 HRAS KRAS MAP2K2 PIK3CA
43
Show member pathways
12.71 AKT1 GNAS HRAS MAP2K2 PIK3CA
44 12.68 CDKN2A ERBB2 HRAS KRAS MAP2K2 PIK3CA
45
Show member pathways
12.67 AKT1 ERBB2 HRAS KRAS MAP2K2 PIK3CA
46
Show member pathways
12.66 HRAS IFNG KRAS MAP2K2 PIK3CA
47
Show member pathways
12.65 AKT1 ERBB2 HRAS KRAS MAP2K2 PIK3CA
48
Show member pathways
12.64 AKT1 ERBB2 HRAS KRAS MAP2K2 PIK3CA
49
Show member pathways
12.59 AKT1 HRAS KRAS MAP2K2 PIK3CA
50
Show member pathways
12.59 AKT1 HRAS IFNG KRAS MAP2K2 PIK3CA

GO Terms for Pancreas Adenocarcinoma

Cellular components related to Pancreas Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.8 AKR7A3 AKT1 CDKN2A CTNNB1 ERBB2 ERCC1
2 intracellular GO:0005622 9.76 CTNNB1 ERBB2 FOXP3 IFNG PIK3CA PTF1A
3 cytoplasm GO:0005737 9.53 AKR7A3 AKT1 CDKN2A CTNNB1 ERBB2 ERCC1

Biological processes related to Pancreas Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.99 AKT1 CTNNB1 HRAS IFNG IL7 KRAS
2 cytokine-mediated signaling pathway GO:0019221 9.95 AKT1 IL7 KRAS PIK3CA TP53
3 negative regulation of cell proliferation GO:0008285 9.93 CDKN2A CTNNB1 FOXP3 HRAS SMAD4 TP53
4 axon guidance GO:0007411 9.91 HRAS KRAS PIK3CA SMAD4
5 cell cycle arrest GO:0007050 9.84 CDKN2A HRAS IFNG TP53
6 positive regulation of protein phosphorylation GO:0001934 9.8 AKT1 ERBB2 HRAS IFNG KRAS
7 positive regulation of MAP kinase activity GO:0043406 9.77 ERBB2 HRAS KRAS
8 cellular response to growth factor stimulus GO:0071363 9.76 AKT1 CTNNB1 ERBB2
9 positive regulation of transcription, DNA-templated GO:0045893 9.76 AKT1 CDKN2A CTNNB1 FOXP3 MAP2K2 PTF1A
10 Ras protein signal transduction GO:0007265 9.73 CDKN2A HRAS KRAS TP53
11 negative regulation of gene expression GO:0010629 9.73 AKT1 CTNNB1 FOXP3 HRAS IFNG MAP2K2
12 phosphatidylinositol 3-kinase signaling GO:0014065 9.67 AKT1 ERBB2 PIK3CA
13 epidermal growth factor receptor signaling pathway GO:0007173 9.67 AKT1 HRAS KRAS PIK3CA
14 positive regulation of organ growth GO:0046622 9.63 AKT1 IL7
15 negative regulation of interleukin-17 production GO:0032700 9.62 FOXP3 IFNG
16 anoikis GO:0043276 9.62 AKT1 PIK3CA
17 ERBB2 signaling pathway GO:0038128 9.62 ERBB2 HRAS KRAS PIK3CA
18 positive regulation of smooth muscle cell apoptotic process GO:0034393 9.61 CDKN2A IFNG
19 response to isolation stress GO:0035900 9.59 HRAS KRAS
20 positive regulation of core promoter binding GO:1904798 9.58 CTNNB1 IFNG
21 hair follicle placode formation GO:0060789 9.57 CTNNB1 GNAS
22 negative regulation of immature T cell proliferation in thymus GO:0033088 9.56 CDKN2A ERBB2
23 cell proliferation GO:0008283 9.5 AKT1 CTNNB1 ERBB2 ERCC1 HRAS SMAD4
24 positive regulation of gene expression GO:0010628 9.28 AKT1 CDKN2A CTNNB1 ERBB2 FOXP3 HRAS
25 positive regulation of transcription by RNA polymerase II GO:0045944 10.08 AKT1 CDKN2A CTNNB1 FOXP3 HRAS PTF1A
26 negative regulation of transcription, DNA-templated GO:0045892 10 CDKN2A CTNNB1 FOXP3 IFNG SMAD4 TP53

Molecular functions related to Pancreas Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein C-terminus binding GO:0008022 9.56 CTNNB1 ERBB2 ERCC1 HRAS
2 protein phosphatase binding GO:0019903 9.54 CTNNB1 ERBB2 TP53
3 I-SMAD binding GO:0070411 9.4 CTNNB1 SMAD4
4 nucleotide binding GO:0000166 9.35 AKT1 ERBB2 HRAS KRAS MAP2K2
5 RNA polymerase II transcription factor binding GO:0001085 9.33 CTNNB1 SMAD4 TP53
6 TFIID-class transcription factor binding GO:0001094 9.32 ERCC1 TP53
7 disordered domain specific binding GO:0097718 8.8 CDKN2A CTNNB1 TP53

Sources for Pancreas Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....